## SEQUENCE LISTING

<110>	PROUDFOOT, AMANDA JEFFREY, SHAW												
<120>	NOVEL CXCL8 ANTAGONISTS												
<130>	ARS-123												
<140> <141>	US 10/573,726 2006-03-28												
<150> <151>	EP 03103909.2 2003-10-22												
<160>	6												
<170>	PatentIn version 3.1												
<210> <211> <212> <213>	1 297 DNA homo sapiens												
<220> <223>	Human CXCL8 coding sequence												
<400> atgactt	1 toca agotggoogt ggototottg goagoottoo tgatttotgo agototgtgt (	60											
gaaggto	gcag ttttgccaag gagtgctaaa gaacttagat gtcagtgcat aaagacatac 12	20											
tccaaac	cett tecaececaa atttateaaa gaaetgagag tgattgagag tggaecaeae 18	30											
tgcgcca	aaca cagaaattat tgtaaagctt tctgatggaa gagagctctg tctggacccc 24	10											
aaggaaa	aact gggtgcagag ggttgtggag aagtttttga agagggctga gaattca 29	97											
<210> <211> <212> <213>	2 72 PRT Homo sapiens												
<220> <223>	Mature human CXCL8												
<400>	2												
Ser Ala 1	Lys Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro 5 10 15												
Phe His	Pro Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro 20 25 30												

His Cys	Ala A 35	sn Thr	Glu	Ile	Ile 40	Val	Lys	Leu	Ser	Asp 45	Gly	Arg	Glu	
Leu Cys 50	Leu A	sp Pro	Lys	Glu 55	Asn	Trp	Val	Gln	Arg 60	Val	Val	Glu	Lys	
Phe Leu 65	Lys A	rg Ala	Glu 70	Asn	Ser									
<210> 3 <211> 297 <212> DNA <213> Artificial sequence														
<220> <223>	CXCL8-	1B3 co	ding	sequ	ience	€								
<400> 3	_	ctggcc	gt gg	gctct	ctto	g gc	agcct	ttcc	tgat	:ttc	tgc	agct	ctgtgt	60
gaaggtgo	cag tt	ttgcca	ag ga	agtgo	taaa	a gaa	actta	agat	gtca	agtg	cat	aaaga	acatac	120
tccaaaco	ctt to	cacccc	aa at	ttat	caaa	a gaa	actga	agag	tgat	tga	gag	tggad	ccacac	180
tgcgccaa	aca ca	gaaatt	at to	gtaaa	gctt	t to	tgato	ggaa	gaga	agct	ctg	tctg	gacccc	240
aaggaaaa	act gg	gtgcag	ga gg	gttgt	ggaç	g gc	gttt	tgg	cgaç	gggct	:ga	gaatt	ca	297
<212> F <213> A	72 PRT	cial s	equer	nce										
<220> <223> M	lature	CXCL8-	-1B3											
<400> 4	Į													
Ser Ala	Lys Gl	lu Leu 5	Arg	Cys	Gln	Cys	Ile 10	Lys	Thr	Tyr	Ser	Lys 15	Pro	
Phe His	Pro Ly 20		Ile	Lys	Glu	Leu 25	Arg	Val	Ile	Glu	Ser 30	Gly	Pro	
His Cys	Ala As 35	sn Thr	Glu	Ile	Ile 40	Val	Lys	Leu	Ser	Asp 45	Gly	Arg	Glu	
Leu Cys 50	Leu As	sp Pro	Lys	Glu 55	Asn	Trp	Val	Gln	Ala 60	Val	Val	Glu	Ala	
Phe Leu 65	Ala Ar	g Ala	Glu 70	Asn	Ser									

3 ARS-123

<210><211><211><212><213>	> 297 > DNA													
<220> <223>														
<400> 5														
atgacticca agetggccgt ggctctcttg gcagccttcc tgatttctgc agetctgtgt														
gaaggtgcag ttttgccaag gagtgctaaa gaacttagat gtcagtgcat aaagacatac														
tccaaacctt tccaccccaa atttatcaaa gaactgagag tgattgagag tggaccacac														
tgegecaaca cagaaattat tgtaaagett tetgatggaa gagagetetg tetggacece														
aaggaaaact gggtgcagag ggttgtggag gcgtttttgg cggcggctga gaattca														
<210> 6 <211> 72 <212> PRT <213> Artificial sequence <220> <223> Mature CXCL8-2B3														
<400>	6													
Ser Ala	a Lys	Glu	Leu 5	Arg	Cys	Gln	Cys	Ile 10	Lys	Thr	Tyr	Ser	Lys 15	Pro
Phe His	s Pro	Lys 20	Phe	Ile	Lys	Glu	Leu 25	Arg	Val	Ile	Glu	Ser 30	Gly	Pro
His Cys	Ala 35	Asn	Thr	Glu	Ile	Ile 40	Val	Lys	Leu	Ser	Asp 45	Gly	Arg	Glu
Leu Cys 50	. Leu	Asp	Pro	Lys	Glu 55	Asn	Trp	Val	Gln	Arg 60	Val	Val	Glu	Ala
Phe Let	ı Ala	Ala	Ala	Glu 70	Asn	Ser								